Gastro-oesophageal reflux disease is a common condition with a complex pathophysiology. Despite the spectrum of abnormalities, gastric acid has a central role in mucosal damage, and the mainstay of medical treatment is suppression of gastric acid secretion. The results of antisecretory treatment as assessed by endoscopic healing are reviewed. H2 receptor antagonists give more rapid symptom relief than placebo and can produce endoscopic improvement in 31-88% of cases depending on the severity of oesophagitis. Complete healing, however, is seen only in 27-45% of patients and these have mainly grades I-II disease. Improved healing rates can be obtained by increasing the degree of acid suppression or the length of treatment. The addition of a prokinetic agent may be beneficial. Omeprazole heals 67-92% of patients overall and although most successful in the lower grades of oesophagitis, can also heal 48-62% of patients with grade IV disease. The degree and rate ofhealing seem to be related to the reduction in oesophageal acid exposure and thus may correlate with the degree and duration of acid suppression over 24 hours obtained by the various treatments. The underlying pathophysiology is unchanged, however, and long term treatment may be needed to maintain remission.
Gastro-oesophageal reflux disease (GORD) is a very common condition in the western world with an estimated incidence of 7% of the adult population.' Reflux of gastric or duodenal contents into the oesophagus gives rise to symptoms of heartburn and regurgitation which are the principle reasons for the widespread consumption of antacid preparations.2 While most patients with mild GORD present with symptoms of heartburn, in more severe cases reflux of gastric contents results in mucosal inflammation, ulceration, or stricture formation. Furthermore, protracted reflux over many years can result in metaplastic changes and the development of Barrett's epithelium.
The pathophysiology of GORD is complex and not yet fully understood. Defective lower oesophageal sphincter (LOS) motility may be the most important abnormality, of which two main types have been identified. 3 Transient relaxation of the lower oesophageal sphincter, lasting 5-35 seconds and independent ofnormal peristalsis, is seen in 60-83% of reflux episodes, and there is impaired suppression of these periods of sphincter relaxation in the supine position in patients with GORD when compared with healthy controls. Loss of the basal lower oesophageal sphincter tone is thought to account for up to 22% of reflux episodes especially in the more severe grades of oesophagitis.4 Absence of basal LOS tone is rarely continuous but may last up to 10 minutes. Both forms of LOS dysfunction can occur in the same patient. Once reflux has occurred, impaired clearance of gastric contents from the oesophagus contributes to the exposure of the mucosa to damaging refluxate. Reduced gastric emptying, the presence of hiatus hernia, and impaired mucosal resistance to injury are also implicated in the pathogenesis of GORD.
Despite this spectrum of abnormalities, the role of gastric acid is considered essential to mucosal damage. Indeed, intraoesophageal acid perfusion has been used for diagnosis, as with the Bernstein acid perfusion test, and 24 hour intraoesophageal pH monitoring has become widely accepted as the standard test to detect reflux.
Thus, the mainstay of medical treatment for GORD has been aimed at eliminating oesophageal acid exposure, either by neutralisation with alkalies or by suppressing gastric acid secretion. The simple measures of weight loss, dietary control, abstinence from smoking, and raising the head of the bed remain important first line recommendations. Raising the bed head by 20 cm significantly augmented the symptomatic improvement seen with ranitidine from 77% to 87% in a group of 71 Klinkenberg-Knol et al performed-ambulatory 24 hour oesophageal pH monitoring in a small group of patients on 60 mg omeprazole. They found that acid reflux was not entirely abolished by even such high doses of omeprazole. Two of their seven patients had pathologically long supine reflux periods.6' This may account for the few patients who fail to heal despite such high dose treatment.
Discussion
The above studies clearly show that increasing the degree of gastric acid suppression increases the healing of reflux oesophagitis in the short term. This does not, however, alter the natural history of the disease. Relapse is common on stopping treatment, with some 20% only remaining in remission at six months and approximately 50% relapsing in under two months. ' 45 56 Maintenance treatment with reduced doses of antisecretory drugs seems to have no advantage over placebo.'862 Sherbaniuk, however, found that longterm treatment with full dose ranitidine could maintain the improvements obtained over one year.28 Omeprazole 10 or 20 mg once daily has been used for maintenance therapy and at 20 mg daily reduces the relapse rate to 20% at one year. Weekend only dosage regimens have been studied but have not proved to be of benefit.63
The disappointing results obtained by the H2 receptor antagonists may be partly explained by the pathophysiology of the condition. Johansson and Tibbling performed gastric secretion tests and 24 hour pH monitoring in a group of 42 patients with reflux oesophagitis.65 They found gastric hypersecretion in 76%, and that basal and peak acid output, number of reflux episodes, and total supine reflux time were significantly more reduced in symptomatic responders than in nonresponders. The basal acid output has also been shown to correlate with the severity of reflux disease; patients with erosive oesophagitis and Barrett's oesophagus have significantly higher basal acid outputs than those with heartburn alone."6 Serum gastrin values are also higher in resistant cases. 67 Collen et al have recently published a study of patients resistant to conventional doses of ranitidine.68 The non-responders had significantly higher basal acid outputs than those who experienced complete symptomatic relief, and 9 of 12 were true hypersecretors (basal acid output > 10 mEq/hour). Symptomatic relief was achieved in 10 of 12 using increased doses of ranitidine (up to 1800 mg/day). They found that basal acid output had to be almost completely suppressed (to below 1 mEq/hour) for heartburn to be relieved. 15 years post marketing surveillance of cimetidine has proved it to be remarkably safe and omeprazole has been used compassionately for up to six years without significant adverse effect.77 While enterochromaffin like cell hyperplasia and gastric carcinoid formation have been reported in rats given long term high dose omeprazole, these changes have since been shown to occur with H2 receptor antagonists such as ranitidine and loxtidine, the hypolipidaemic compound ciprofibrate or after partial fundectomy. [78] [79] [80] This phenomenom seems to be due to the hypergastrinaemia associated with acid suppression achieved by a variety of means, rather than a direct effect of any of the agents, and furthermore is reversible by antrectomy. 81 82 Prolonged hypochlorhydria, however, may predispose to late gastric carcinoma as observed some 20 years after surgery for benign peptic ulcer disease.8384 Experimentally, at least, operations resulting in duodenogastric bile reflux increase the susceptibility of the gastric mucosa to neoplastic change. 85 It is thought that a high intragastric pH promotes bacterial overgrowth which converts dietary nitrates and nitrites into carcinogenic N-nitroso compounds. Bile reflux seems to be involved in carcinogenesis, but whether by the formation of cocarcinogens or as a promoter by increasing mucosal permeability to initiating carcinogens is uncertain.86 Until these matters are resolved, particularly for the younger patient, there remains a role for surgery in the management of GORD. 
